UAMC-3203
Based on 10 publication(s) in Google Scholar
UAMC-3203 is a potent and selective Ferroptosis inhibitor with an IC50 of 12 nM.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 2271358-64-4
- Formula: C25H37N5O2S
- Molecular Weight:471.66
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Ferroptosis Compound Library
HY-L051
-
Highly Selective Inhibitors Library
HY-L158
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) UAMC-3203
More- Nat Cell Biol. 2025 Aug;27(8):1288-1300. [Abstract]
- Cell Death Differ. 2025 Oct 7. [Abstract]
- Acta Neuropathol. 2024 Jun 22;147(1):106. [Abstract]
- Cell Biol Toxicol. 2022 Jun;38(3):505-530. [Abstract]
- Acta Neuropathol Commun. 2023 Jul 25;11(1):121. [Abstract]
- Bioorg Chem. 2024 Jun:147:107412. [Abstract]
- J Neurochem. 2025 Oct;169(10):e70246. [Abstract]
- Sci Rep. 2024 Aug 30;14(1):20180. [Abstract]
- Res Sq. 2024 Jul 09.
- Research Square Print. October 26th, 2022.
Customer Validation & Images
-
WB
-
IF
-
Histological Imaging/Staining
-
ELISA
Biological Activity
IC50: 12 nM (Ferroptosis)[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wild type mice derived from a Gpx4 fl/fl breeding[1]
-
Dosage:20 µmol/kg
-
Administration:Injected intraperitoneally; daily, over a period of 4 weeks
-
Result:No toxicity was observed.
Chemical Information
-
CAS No. 2271358-64-4
-
Appearance Solid
-
Molecular Weight 471.66
-
Formula C25H37N5O2S
-
Color White to off-white
-
SMILES
O=S(C(C=C1NCC2=CC=CC=C2)=CC=C1NC3CCCCC3)(NCCN4CCNCC4)=O
-
Synonyms
FXT-001
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Cell Biol
2025 Aug;27(8):1288-1300. PMID: 40681752 -
Cell Death Differ
PDK4-driven lactate accumulation facilitates LPCAT2 lactylation to exacerbate sepsis-induced acute lung injury. [Abstract]2025 Oct 7. PMID: 41057687 -
Acta Neuropathol
Ferroptosis inhibitor improves outcome after early and delayed treatment in mild spinal cord injury. [Abstract]2024 Jun 22;147(1):106. PMID: 38907771 -
Cell Biol Toxicol
Protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injury. [Abstract]2022 Jun;38(3):505-530. PMID: 34401974 -
Acta Neuropathol Commun
Ferroptosis induces detrimental effects in chronic EAE and its implications for progressive MS. [Abstract]2023 Jul 25;11(1):121. PMID: 37491291 -
Bioorg Chem
Identification of FTY720 and COH29 as novel topoisomerase I catalytic inhibitors by experimental and computational studies. [Abstract]2024 Jun:147:107412. PMID: 38696845 -
J Neurochem
Neuronal Damage Induced by Gradual Oxidative Stress in iPSC-Derived Neurons: Implications for Ferroptosis Involvement and ALS Drug Evaluation. [Abstract]2025 Oct;169(10):e70246. PMID: 41017138 -
Sci Rep
UAMC-3203 inhibits ferroptosis and promotes functional recovery in rats with spinal cord injury. [Abstract]2024 Aug 30;14(1):20180. PMID: 39215144
UAMC-3203 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2024 Aug 30;14(1):20180. [Abstract]
The expressions of NRF2 and HO-1 were detected by Western blot assays on day 3 after SCI treated with UAMC-3203 (5 mg/kg, i.p.).
UAMC-3203 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2024 Aug 30;14(1):20180. [Abstract]
DHE (dihydroethidium) staining of spinal cord tissue on day 1 after SCI treated with UAMC-3203 (5 mg/kg, i.p.).
UAMC-3203 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2024 Aug 30;14(1):20180. [Abstract]
HE-stained and LFB-stained transverse sections of spinal cords from sham group, SCI group, SCI + UAMC-3203 (5 mg/kg, i.p.) (U) group, and SCI + U + B group 28 days after the injury.
UAMC-3203 purchased from MedChemExpress. Usage Cited in: Sci Rep. 2024 Aug 30;14(1):20180. [Abstract]
The concentration of IL-1β, IL-4, IL-10 and TNFα in sham group, SCI group, SCI + UAMC-3203 (5 mg/kg, i.p.) (U) group, and SCI + U + B 7 days after the injury.
-
-
Solvent & Solubility
DMSO : 250 mg/mL (530.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (537 KB)
- English - EN (537 KB)
- Français - FR (537 KB)
- Deutsch - DE (537 KB)
- Norwegian - NO (537 KB)
- Español - ES (537 KB)
- Swedish - SV (537 KB)
- Italian - IT (537 KB)
- Portuguese - PT (537 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1202 mL | 10.6009 mL | 21.2017 mL | 53.0043 mL |
| 5 mM | 0.4240 mL | 2.1202 mL | 4.2403 mL | 10.6009 mL | |
| 10 mM | 0.2120 mL | 1.0601 mL | 2.1202 mL | 5.3004 mL | |
| 15 mM | 0.1413 mL | 0.7067 mL | 1.4134 mL | 3.5336 mL | |
| 20 mM | 0.1060 mL | 0.5300 mL | 1.0601 mL | 2.6502 mL | |
| 25 mM | 0.0848 mL | 0.4240 mL | 0.8481 mL | 2.1202 mL | |
| 30 mM | 0.0707 mL | 0.3534 mL | 0.7067 mL | 1.7668 mL | |
| 40 mM | 0.0530 mL | 0.2650 mL | 0.5300 mL | 1.3251 mL | |
| 50 mM | 0.0424 mL | 0.2120 mL | 0.4240 mL | 1.0601 mL | |
| 60 mM | 0.0353 mL | 0.1767 mL | 0.3534 mL | 0.8834 mL | |
| 80 mM | 0.0265 mL | 0.1325 mL | 0.2650 mL | 0.6626 mL | |
| 100 mM | 0.0212 mL | 0.1060 mL | 0.2120 mL | 0.5300 mL |
Powered by Bioz